Icon

TRISENOX (nda021248)- (1MG/ML,2MG/ML)

ARSENIC TRIOXIDE CEPHALON
1MG/ML,2MG/ML
Yes No
2018-Nov-10 Expired
None None
None No
TRISENOX is an arsenical indicated: • In combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression. • For induction of remission and consolidation in patients with APL who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.
11 1 11
Total Other Developers 6
Drugs with Suitability No
1MG/ML ** ** - - -
2MG/ML ** ** - - -
NDA Sales Available Total Generic Sales Available
No 8
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ***** ****** ***** ************ ******* *********** **** **. **, ******* ******* ******** ****, ******* - ***** *. *. **. **, ******, *** : ******, *********, ******* ******, ***** (***) ***
****** ********* **** *** ********* *.*.* *** *********** *** ***** ******* **, ********, ****** *****, ***** (***) ***
****** ********* **** *** ********* *.*.* *********** *** ***** ******* **, ********, ****** *****, ***** (***) ***
****** ******* ****** *** ******* *************** **** *********** *** ********* **, ********, ****** ****, *********** (***) ***
****** ****** ****** ******** ******* ******* *********** **** **. *-*, *-*, *-**, *****-*** *******-********* ******-********* *************, *************, ** ******, ***** (***) ***
****** ****** ****** ***** *** (*****) ***. *********** ****** ****** ********** ******, ******, ***********, *******, ***** (***) ***
****** ***** ****** *** ***** ****** ******* *********** **** * & **** **, ***** *, ***** *, ************* ******* ******** **** (**** ), *******, *************, ****** ******* ******, ***** (***) ***
****** ********* *** ************ ******* ******* *********** ************ ********, ****-**, ****** ***. ****& **** ** ****, ********* (*******), ********* (******), ********** ********, ********* ******, ***** (***) ***
****** ***** ****** *** ******** ******* ******* *****--** ******* *********** **. ***, ***** *** **., ***. *,, ******* ****., ******* ****, ******, ****** (***) ***
****** ****** ****** ******** **** *********** *********** ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.